Wednesday, July 10, 2024 7:58:25 AM
Recent AMLX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/25/2024 09:56:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/16/2024 09:39:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/09/2024 08:05:06 PM
- Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 08/28/2024 12:30:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/26/2024 10:49:57 PM
- Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration • Business Wire • 08/12/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:14:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:09:33 AM
- Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 • Business Wire • 08/05/2024 01:00:00 PM
- Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome • Business Wire • 08/02/2024 01:00:00 PM
- Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 07/18/2024 11:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 11:09:00 AM
- Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation • Business Wire • 07/10/2024 11:00:00 AM
- Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide • Business Wire • 07/09/2024 08:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:52:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:50:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:49:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:07:30 PM
- Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference • Business Wire • 06/04/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 11:36:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:12:01 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:05:38 AM
- Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results • Business Wire • 05/09/2024 11:00:00 AM
- Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference • Business Wire • 05/08/2024 01:00:00 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM
Maybacks Global Entertainment and Lingerie Fighting Championships Enter Into Broadcast And Revenue Sharing Agreement • AHRO • Sep 26, 2024 8:30 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM